Cyclophosphamide

Evidence Level: L5

Predicted Indications: 2

Cyclophosphamide

Pharmacist Assessment Report

Cyclophosphamide: Vertebral anomalies and variable endocrine and T-cell dysfunction

One-Sentence Summary

Cyclophosphamide is an alkylating chemotherapy and immunosuppressive agent that is marketed in Canada. The TxGNN model predicts it may be relevant to vertebral anomalies and variable endocrine and T-cell dysfunction, but the prediction is a computational output only: no clinical trials and no publications in the data compiled for this report address this condition.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Vertebral anomalies and variable endocrine and T-cell dysfunction
TxGNN Prediction Score	0.9938
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 10 of 10)
Number of DINs	10 (marketed: 10)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Cyclophosphamide is a well-known cytotoxic and immunosuppressive agent used across many cancers and immune-mediated conditions.

No mechanistic rationale for this prediction has been identified. The high TxGNN score is a computational result only. Cyclophosphamide suppresses T-cell function, which is not an obvious therapeutic fit for a congenital syndrome that already involves T-cell dysfunction, and it could be harmful in that setting. The prediction should be treated as a hypothesis with no supporting evidence at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02546744	Cyclophosphamide for Injection USP	Injection (per product name)	Not available
02547686	Cyclophosphamide for Injection USP	Injection (per product name)	Not available
02546736	Cyclophosphamide for Injection USP	Injection (per product name)	Not available
02241795	Procytox Tab 25 mg	Tablet (per product name)	Not available
02241796	Procytox Tab 50 mg	Tablet (per product name)	Not available

All 10 licences on record are valid single-ingredient products. The table above lists the first five.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (alkylating agent, nitrogen mustard class)
Myelosuppression Risk	High (leukopenia and neutropenia are expected; please refer to the package insert)
Emetogenicity Classification	Moderate to high, dose-dependent
Monitoring Items	Complete blood count with differential, liver and renal function, urinalysis for haematuria
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Drug Interactions: 100 interactions were recorded. Those listed include moderate-level interactions with amphotericin B products (including lipid complex, cholesteryl sulfate and liposomal forms), bupropion, aprepitant, metronidazole, nitisinone and troglitazone. Several sulfonylurea and related antidiabetic agents (chlorpropamide, acetohexamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide, nateglinide, repaglinide) are also listed as moderate. Levofloxacin and ondansetron are listed as minor.

For warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: No trials or publications study this condition, no mechanistic rationale has been identified, and cyclophosphamide’s T-cell suppression could be harmful in a disorder involving T-cell dysfunction. The score alone is not sufficient to justify further development.

To proceed, the following is needed:

A plausible biological rationale linking cyclophosphamide to this condition
Mechanism-of-action data
Package insert warnings and contraindications, to complete safety screening
Any case-level or preclinical evidence in this specific disease before further consideration

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.